SCHEMBL322172

SCHEMBL322172

CC(C)(C)OC(=O)N1CC[C@H](N)C1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.51
RECQL P46063 1/20 0.49
EPHX1 P07099 1/20 0.49
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
THRB P10828 1/20 0.48
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
GPR119 Q8TDV5 4/20 0.46
NR1H2 P55055 1/20 0.45
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
USP30 Q70CQ3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8785 1.00 HPGD (0.51) HPGDRECQLEPHX1MAPTKDM4E
SCHEMBL241779 1.00 HPGD (0.51) HPGDRECQLEPHX1MAPTKDM4E
Hydrochloric Acid SCHEMBL861053 0.98 HPGD (0.50) HPGDRECQLEPHX1MAPTKDM4E
Hydrochloric Acid SCHEMBL14746009 0.98 HPGD (0.50) HPGDRECQLEPHX1MAPTKDM4E
Hydrochloric Acid SCHEMBL2497038 0.98 HPGD (0.50) HPGDRECQLEPHX1MAPTKDM4E
Acetic Acid SCHEMBL2493436 0.95 HPGD (0.48) HPGDRECQLEPHX1MAPTKDM4E
Carbamic Acid SCHEMBL30731480 0.95 HPGD (0.48) HPGDRECQLEPHX1MAPTKDM4E
Trifluoroacetic Acid SCHEMBL27848482 0.91 HPGD (0.44) HPGDRECQLEPHX1MAPTKDM4E
SCHEMBL181566 0.90 MAPT (0.55) HPGDRECQLEPHX1MAPTKDM4E
SCHEMBL376485 0.90 MAPT (0.55) HPGDRECQLEPHX1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119039201-A Synthesis method of (S) -1-tert-butoxycarbonyl-3-aminopyrrolidine 苏州汉德创宏生化科技有限公司 2024-11-29 CN claimed
CN-117143083-A Synthesis method of VEGFR inhibitor Vorolianib 沈阳药科大学 2023-12-01 CN claimed
CN-112094268-B Compound WEZ series, preparation method thereof and application of compound WEZ series in preparation of medicines 南京韦尔优众医药有限公司 2021-02-09 CN claimed
CN-112094268-A Compound WEZ series, preparation method thereof and application of compound WEZ series in preparation of medicines 南京韦尔优众医药有限公司 2020-12-18 CN claimed
US-7060782-B2 Process for a two stage melt polymerization for the production of polybenzimidazole having an improved solid state polymerization PBI PERFORMANCE PRODUCTS, INC. (US) 2006-06-13 US claimed
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2026-05-26 US disclosed
US-12637453-B2 Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-26 US disclosed
CN-122079979-A Benzofuran derivative and medical application thereof 2026-05-26 CN disclosed
CN-122080012-A Thienopyrimidine derivative, preparation method, application and pharmaceutical composition thereof 2026-05-26 CN disclosed
CN-122071469-A PARG inhibitor and preparation method and application thereof 烟台新药创制山东省实验室 2026-05-22 CN disclosed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
EP-4105216-B1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-05-20 EP disclosed
EP-1080069-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-07 EP disclosed
EP-1031563-A1 SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-08-30 EP disclosed
US-6090802-A BACTERICIDE SANKYO COMPANY, LIMITED (JP) 2000-07-18 US disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 WO disclosed
US-5866564-A STABILITY SANKYO COMPANY, LIMITED (JP) 1999-02-02 US disclosed
EP-0882728-A1 1-METHYLCARBAPENEM DERIVATIVES SANKYO COMPANY LIMITED (JP) 1998-12-09 EP disclosed
US-5712267-A Carbapenem derivatives, their preparation and their use as antibiotics SANKYO COMPANY,. LIMITED (JP) 1998-01-27 US disclosed
EP-0560613-A1 Antimicrobial carbapenem derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1993-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP1, USP10 HPGD 2931/4885RECQL 691/4885EPHX1 3856/4885
US-12637453-B2 Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof MAP3K1, MAP3K3, MAPK1 HPGD 1857/4885RECQL 2093/4885EPHX1 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.